REGENERON PHARMACEUTICALS (RGO.DE) Stock Price, Forecast & Analysis
Europe • Frankfurt Stock Exchange • FRA:RGO • US75886F1075
RGO.DE Key Statistics, Chart & Performance
The current stock price of RGO.DE is 651.8 EUR. In the past month the price increased by 0.59%.
RGO.DE Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to RGO.DE.
RGO.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to RGO.DE. RGO.DE gets an excellent profitability rating and is at the same time showing great financial health properties.
RGO.DE Financial Highlights
Over the last trailing twelve months RGO.DE reported a non-GAAP Earnings per Share(EPS) of 37.31. The EPS decreased by -2.76% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 32.13% | ||
| ROA | 11.4% | ||
| ROE | 14.79% | ||
| Debt/Equity | 0.09 |
RGO.DE Forecast & Estimates
36 analysts have analysed RGO.DE and the average price target is 730.57 EUR. This implies a price increase of 12.08% is expected in the next year compared to the current price of 651.8.
For the next year, analysts expect an EPS growth of 4.68% and a revenue growth 9.08% for RGO.DE
RGO.DE Ownership
RGO.DE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 1AE | ARGENX SE | 28.15 | 43.912B | ||
| ARGX | ARGENX SE | 27.8 | 43.875B | ||
| 22UA | BIONTECH SE-ADR | N/A | 22.723B | ||
| ABVX | ABIVAX SA | N/A | 7.923B | ||
| 2X1 | ABIVAX SA | N/A | 7.923B | ||
| GXE | GALAPAGOS NV | N/A | 1.874B | ||
| GLPG | GALAPAGOS NV | N/A | 1.871B | ||
| IVA | INVENTIVA SA | N/A | 1.027B | ||
| NANO | NANOBIOTIX | N/A | 1.009B | ||
| 6IV | INVENTIVA SA | N/A | 978.821M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Frankfurt Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About RGO.DE
Company Profile
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. The company is headquartered in Tarrytown, New York. The firm invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The firm is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.
Company Info
REGENERON PHARMACEUTICALS
777 Old Saw Mill River Road
Tarrytown NEW YORK US
Employees: 15106
Phone: 17813705000
REGENERON PHARMACEUTICALS / RGO.DE FAQ
Can you describe the business of REGENERON PHARMACEUTICALS?
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. The company is headquartered in Tarrytown, New York. The firm invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The firm is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.
Can you provide the latest stock price for REGENERON PHARMACEUTICALS?
The current stock price of RGO.DE is 651.8 EUR. The price decreased by -0.12% in the last trading session.
What is the dividend status of REGENERON PHARMACEUTICALS?
REGENERON PHARMACEUTICALS (RGO.DE) has a dividend yield of 0.49%. The yearly dividend amount is currently 0.
How is the ChartMill rating for REGENERON PHARMACEUTICALS?
RGO.DE has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Which stock exchange lists RGO stock?
RGO.DE stock is listed on the Frankfurt Stock Exchange exchange.
What is the Price/Earnings (PE) ratio of REGENERON PHARMACEUTICALS (RGO.DE)?
The PE ratio for REGENERON PHARMACEUTICALS (RGO.DE) is 17.47. This is based on the reported non-GAAP earnings per share of 37.31 and the current share price of 651.8 EUR.
What is the market capitalization of RGO stock?
REGENERON PHARMACEUTICALS (RGO.DE) has a market capitalization of 68.50B EUR. This makes RGO.DE a Large Cap stock.